Small biotech — big am­bi­tions. Vi­r­a­lyt­ics’ on­colyt­ics ther­a­py makes the show­case round at #AACR17 with pos­i­tive com­bo snap­shot

PHO­TO: © AACR/Todd Buchanan 2017


WASH­ING­TON, DC — When you talk to Vi­r­a­lyt­ics CEO Mal­colm Mc­Coll, he has a habit of re­mind­ing his lis­ten­ers about just how small his pub­lic Aus­tralian biotech is. Small staff, small stud­ies. And there are just so many things a small biotech can do.

Mal­colm Mc­Coll

But he and his com­pa­ny {ASX: VLA} have some very big am­bi­tions in the hot on­colyt­ics field, build­ing their hopes around a ther­a­py called Cox­sack­ievirus A21 (or CVA21 or Ca­vatak). And to­day the pow­ers that be at AACR are steer­ing their lat­est da­ta in­to the show­case morn­ing round.

At the time of the da­ta cut­off for AACR, the com­pa­ny had evalu­able re­spons­es from 22 pa­tients in a small melanoma study com­bin­ing their ther­a­py — us­ing a non­genet­i­cal­ly al­tered cold virus to in­fect can­cer cells, de­signed to de­stroy them and re­cruit T cells for a fol­lowup at­tack — with Yer­voy.

In­ject­ed di­rect­ly in­to le­sions, re­searchers tracked an over­all re­sponse rate of 50%, with 4 pa­tients reg­is­ter­ing a com­plete re­sponse and 7 pa­tients ex­pe­ri­enc­ing a par­tial re­sponse. The me­di­an du­ra­tion of re­sponse was not yet reached, “with a num­ber of re­spons­es greater than six months and sev­er­al still on­go­ing” — a sig­nal of po­ten­tial dura­bil­i­ty.

Among 11 pa­tients who had dis­ease pro­gres­sion fol­low­ing ear­li­er treat­ment with an im­mune check­point in­hibitor, 4 had a re­sponse. The oth­er 7 re­spon­ders had not been treat­ed ear­li­er with a check­point.

“The pre­lim­i­nary over­all re­sponse rate of 50% is very pos­i­tive be­cause pre­vi­ous re­ports in­di­cate an 11% over­all re­sponse rate for ip­il­i­mum­ab alone and an ap­prox­i­mate­ly 28% over­all re­sponse rate for CVA21 alone,” said Bren­dan Cur­ti, the pri­ma­ry in­ves­ti­ga­tor who runs a melanoma clin­ic in Port­land.

The safe­ty pro­file al­so looked good. Of 25 pa­tients who could be eval­u­at­ed for safe­ty, two had grade 3 or high­er ip­il­i­mum­ab-re­lat­ed ad­verse events. No CVA21-re­lat­ed ad­verse events of grade 3 or high­er were re­port­ed.

The next step, says Mc­Coll, will be to add sev­er­al dozen pa­tients to the study who have failed a check­point ther­a­py and then see if they have the kind of re­sults that can be used to mount a reg­is­tra­tion study.

It’s con­ceiv­able, he says, that reg­u­la­tors could sign off on a sin­gle arm study with a cou­ple of hun­dred pa­tients for that piv­otal try, that’s “some­thing a small Aus­tralian com­pa­ny could take on.”

Vi­r­a­lyt­ics has jumped on to a stage that in­cludes a grow­ing num­ber of on­colyt­ics play­ers, like PsiOxus, which re­cent­ly signed a stand­out $936 mil­lion deal to part­ner with Bris­tol-My­ers, which was al­ready help­ing with a com­bo of Op­di­vo plus their on­colyt­ic virus.

All these com­pa­nies are com­ing in be­hind Am­gen’s T-Vec, the pi­o­neer­ing drug in the field which they be­lieve is ripe for sur­pass­ing its re­sults in the clin­ic.

So far, Mc­Coll’s small Aus­tralian com­pa­ny has paid the freight on the work, with Mer­ck pro­vid­ing Keytru­da for com­bi­na­tions in the clin­ic. At some point, if things con­tin­ue to progress, Mc­Coll al­so ex­pects to strike a mon­ey/mar­ket­ing deal.

“I don’t think a small Aus­tralian com­pa­ny will be mar­ket­ing a drug in the US,” he says with a smile. Af­ter to­day, he might find a few new op­por­tu­ni­ties on that score.

How Pa­tients with Epilep­sy Ben­e­fit from Re­al-World Da­ta

Amanda Shields, Principal Data Scientist, Scientific Data Steward

Keith Wenzel, Senior Business Operations Director

Andy Wilson, Scientific Lead

Real-world data (RWD) has the potential to transform the drug development industry’s efforts to predict and treat seizures for patients with epilepsy. Anticipating or controlling an impending seizure can significantly increase quality of life for patients with epilepsy. However, because RWD is secondary data originally collected for other purposes, the challenge is selecting, harmonizing, and analyzing the data from multiple sources in a way that helps support patients.

$DNA is once again on NYSE; FDA clears Soliris chal­lenger for the mar­ket; Flag­ship’s think­ing big again with eR­NA; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

I still remember the uncertainty in the air last year when nobody was sure whether ASCO would cancel their in-person meeting. But it’s now back again for the second virtual conference, and Endpoints News is here for it. Check out our 2-day event reviewing the landscape of cancer R&D and send news our way.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.

Re­gen­eron's Evkeeza shows promise in curb­ing high triglyc­erides, but will ge­net­ic dis­par­i­ties lim­it use?

When Regeneron scored an early approval for lipid lowering antibody Evkeeza back in February, the drugmaker cracked open a new pathway to lower abnormally high cholesterol levels. Now, Regeneron is chasing high triglycerides as well with some promising mid-stage data — but will genetic restrictions limit the drug’s use?

Regeneron’s Evkeeza (evinacumab) cut median triglyceride levels by more than 800 mg/dL (57%) in patients with a rare disorder causing abnormally high triglyceride levels compared with an overall increase of 50 mg/dL (1.8%) in participants on placebo, according to Phase II data presented Sunday at the virtual American College of Cardiology meeting.

Michael Dell (Richard Drew, AP Images)

'Dude, you're get­ting a Del­l' — as a new deep-pock­et biotech in­vestor

What happens when you marry longtime insiders in the global biotech VC game with the family fund of tech billionaire Michael Dell, a synthetic biology legend out of MIT and Harvard and the former director of the NCI?

Today, the answer is a newly financed, $200 million biotech SPAC now cruising the industry for a top player interested in finding a short cut to Nasdaq.

Orion Biotech Opportunities priced their blank check company today, raising $200 million with Dell’s multibillion-dollar MSD group’s commitment on investing another $20 million in a forward-purchase agreement.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

As­traZeneca's Farx­i­ga missed big on Covid-19 study, but it's tak­ing SGLT2 safe­ty da­ta as a sil­ver lin­ing

AstraZeneca hasn’t seen many setbacks in recent months for SGLT2 inhibitor Farxiga, which broke ground in heart failure and kidney disease regardless of diabetes diagnosis. But the British drugmaker had to admit defeat in taking Farxiga into Covid-19, but follow-up results add a bit of a silver lining to that trial’s safety data.

Of hospitalized Covid-19 patients dosed with AstraZeneca’s Farxiga, 11.2% experienced an organ failure or died after 30 days of therapy compared with 13.8% of those given placebo, according to follow-up data from the DARE-19 study revealed Sunday at the virtual American College of Cardiology meeting.

Vas Narasimhan (Photographer: Simon Dawson/Bloomberg via Getty Images)

No­var­tis whiffs on En­tresto study af­ter heart at­tacks — but that does­n't mean it's go­ing down qui­et­ly

If Novartis learned one thing from its interaction with the FDA over its latest heart failure approval for Entresto, it was that missing a primary endpoint may not be the nail in the coffin. Now, Entresto has missed again on a late-stage study in high-risk heart patients, and it’s already sowing the seeds for a path forward regardless.

Novartis’ Entresto couldn’t best standard-of-care ramipril in staving off a composite of deaths and heart failure events in patients with left ventricular systolic dysfunction and/or pulmonary congestion who have had a prior heart attack, according to topline data from the Phase III PARADISE-MI study revealed Saturday at the virtual American College of Cardiology meeting.

Pfiz­er, Bris­tol My­er­s' Eliquis flops in post-heart surgery pa­tients, spurring an 'un­ex­plained sig­nal' in cer­tain deaths

Pfizer and Bristol Myers Squibb’s non-warfarin blood thinner Eliquis has raced out to become the most prescribed drug of its class on the market — even overtaking warfarin’s long-time lead. But in tricky-to-treat patients after a valve replacement, an investigator-sponsored study couldn’t turn up benefit and raised a troubling safety signal.

Eliquis failed to show benefit over standard of care in preventing serious clinical outcomes after a transaortic valve replacement (TAVR) and was linked to an “unexplained signal” in a subset of populations with a higher rate of non-CV deaths who did not need blood thinners apart from the surgery, according to data presented Saturday at the virtual American College of Cardiology meeting.

Gene ther­a­py from Bio­gen's $800M buy­out flops in mid-stage study, deal­ing blow to new am­bi­tions

The #2 candidate from Biogen’s $800 million ocular gene therapy buyout has failed in a mid-stage trial, dealing an early blow to the big biotech’s plans to revitalize its pipeline with new technologies.

Biogen announced that the candidate, an experimental treatment for a rare and progressive form of blindness called X-linked retinitis pigmentosa (XLRP), failed to sufficiently improve vision in patients’ treated eye — patients only received an injection in one eye — after a year, on a standard scale, compared to their untreated eye. The company said they saw “positive trends” on several secondary endpoints, including visual acuity, but declined to say whether the trial actually hit any of those endpoints.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.

Abbie Celniker (L) and Rob Sims (Flare)

A Third Rock-backed play­er charts a new course against tran­scrip­tion fac­tors. Do 'switch sites' hold the mag­ic sauce?

Long known for their role in guiding gene expression but considered “undruggable,” DNA binding transcription factors have long been a Holy Grail for drug developers. Now, a new startup from Third Rock Ventures thinks it could have the juice to get after transcription factors once and for all — and it all started with a “flare” of inspiration from an article out of an Oxford lab.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.